Ian Blackman was appointed as Chief Financial Officer effective April 27, 2026, succeeding Interim CFO Adam E. Drapczuk III. The new CFO will receive an annual base salary of $250,000. A performance-based cash bonus for 2026 is tied to EBITDA targets ranging from $4 million to $8 million. Blackman was granted 160,000 stock options under the 2019 Long-Term Incentive Plan, with a five-year term. The appointment is strategically timed to support the integration of regenerative biomaterial products acquired from Celularity Inc.